ArticleNature communications2019
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 66 citations in OpenAlex.
- Multi-omics and machine learning integration of diverse cell death pathways optimize risk stratification and inform drug therapy in Wilms tumor.Discover oncology · 2026Article
- The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.Nature reviews. Urology · 2026Review
- Expression pattern of cancer-associated cellular senescence genes in clear cell renal cell carcinoma distinguishes tumor subclasses with clinical implications.Scientific reports · 2025Article
- Identifying a prognostic signature for clear cell renal cell carcinoma: the convergence of single-cell and bulk sequencing with machine learning.Frontiers in cell and developmental biology · 2025Article
- Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma.Communications biology · 2024Article
- Genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort.Nature communications · 2023Article
- Integrated analysis of racial disparities in genomic architecture identifies a trans-ancestry prognostic subtype in bladder cancer.Molecular oncology · 2023Article
- Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications.Cancers · 2023Review
- An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.International journal of molecular sciences · 2023Article
- Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in breast cancer.Scientific data · 2023Article
- Low Expression of TSTD2 Serves as a Biomarker for Poor Prognosis in Kidney Renal Clear Cell Carcinoma.International journal of general medicine · 2023Article
- Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.Cancer communications (London, England) · 2022Article
- The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma.Journal of the National Cancer Center · 2022Article
- Interleukin 17 and Its Involvement in Renal Cell Carcinoma.Journal of clinical medicine · 2022Review
- Comprehensive characterization of clonality of driver genes revealing their clinical relevance in colorectal cancer.Journal of translational medicine · 2022Article
- COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks.European journal of medical research · 2022Article
- Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma.Genome medicine · 2022Article
- Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.Frontiers in immunology · 2022Article
- Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma.BioMed research international · 2022Article
- Construction of a novel prognostic signature based on the composition of tumor-infiltrating immune cells in clear cell renal cell carcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investigated extensively but its evolution patterns remained unclear. Here we analyze the clonal architectures of 473 patients from three different populations. We find that the mutational signatures vary substantially across different populations and evolution stages. The evolution patterns of ccRCC have great inter-patient heterogeneities, with del(3p) being regarded as the common earliest event followed by three early departure points: VHL and PBRM1 mutations, del(14q) and other somatic copy number alterations (SCNAs) including amp(7), del(1p) and del(6q). We identify three prognostic subtypes of ccRCC with distinct clonal architectures and immune infiltrates: long-lived patients, enriched with VHL but depleted of BAP1 mutations, have high levels of Th17 and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.